Sol-Gel halts studies for rare disease therapy after trial setback
Source: SeekingAlpha
2025-12-17 08:25:25 ET
More on Sol-Gel Technologies
- Seeking Alpha’s Quant Rating on Sol-Gel Technologies
- Historical earnings data for Sol-Gel Technologies
- Financial information for Sol-Gel Technologies
Read the full article on Seeking Alpha
For further details see:
Sol-Gel halts studies for rare disease therapy after trial setback
Sol-Gel Technologies Ltd.
NASDAQ: SLGL
SLGL Trading
14.85% G/L:
$87.23 Last:
10,600 Volume:
$85.28 Open:
SLGL Latest News
December 17, 2025 07:00:00 am
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
November 20, 2025 07:30:00 am
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
SLGL Stock Data
$179,681,649
776,949
16.15%
7
N/A
Biotechnology & Life Sciences
Healthcare
IL
Ness Ziona
